Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Heartseed, Inc. ( (JP:219A) ) has provided an announcement.
Heartseed Inc. has announced a collaboration with Japan Lifeline Co., Ltd. for the supply of a delivery catheter system, which is crucial for their HS-005 clinical trial in Japan. The trial involves a catheter-based administration of allogeneic iPS cell-derived cardiomyocyte spheroids, and the company aims to submit the clinical trial application by the end of 2025, with no changes to their financial forecast.
The most recent analyst rating on (JP:219A) stock is a Hold with a Yen3791.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.
More about Heartseed, Inc.
Heartseed Inc. operates in the biotechnology industry, focusing on regenerative medicine. The company specializes in developing therapies using allogeneic iPS cell-derived cardiomyocyte spheroids, primarily targeting heart disease treatment.
Average Trading Volume: 945,160
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen86.34B
See more data about 219A stock on TipRanks’ Stock Analysis page.